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Abstract
Background: It has been reported that treatment of DENV-infected cultures with Lovastatin (LOV), can affect viral assembly.
The objective of this study was to evaluate the effect of LOV on the survival rate and viremia levels of DENV-2-infected
AG129 mice.
Methodology/Principal Findings: Mice were inoculated with 16106 plaque-forming units (PFU/ml) of DENV-2 and treated
with LOV (200 mg/kg/day). Pre-treatment with one or three doses of LOV increased the survival rate compared to untreated
mice (7.3 and 7.1 days, respectively, compared to 4.8 days). Viremia levels also decreased by 21.8% compared to untreated
mice, but only in the group administered three doses prior to inoculation. When LOV was administered after viral
inoculation, the survival rate increased (7.3 days in the group treated at 24 hpi, 6.8 days in the group treated at 48 hpi and
6.5 days in the group treated with two doses) compared to the untreated group (4.8 days). Interestingly, the serum viral
titer increased by 24.6% in mice treated at 48 hpi with a single dose of LOV and by 21.7% in mice treated with two doses (at
24 and 48 hpi) of LOV compared to untreated mice. Finally histopathological changes in the liver and spleen in infected and
untreated mice included massive extramedullary erythropoiesis foci and inflammatory filtration, and these characteristics
were decreased or absent in LOV-treated mice.
Conclusions/Significance: Our results suggest that the effect of LOV on viremia depends on the timing of treatment and on
the number of doses administered. We observed a significant increase in the survival rate in both schemes due to a delay in
the progression of the disease. However, the results obtained in the post-treatment scheme must be handled carefully
because this treatment scheme increases viremia and we do not know how this increase could affect disease progression in
humans.
Citation:Martinez-Gutierrez M, Correa-London˜o LA, Castellanos JE, Gallego-Go´mez JC, Osorio JE (2014) Lovastatin Delays Infection and Increases Survival Rates in
AG129 Mice Infected with Dengue Virus Serotype 2. PLoS ONE 9(2): e87412. doi:10.1371/journal.pone.0087412
Editor: Pierre Roques, CEA, France
Received July 10, 2013; Accepted December 27, 2013; Published February 21, 2014
Copyright:  2014 Martinez-Gutierrez et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which
permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was supported by COLCIENCIAS (Departamento Administrativo de Ciencia, Tecnologı´a e Innovacio´n) grant No. 111549326092. M.M.G.
received a Ph.D. Fellowship (1308-489-25267) from COLCIENCIAS (http://www.colciencias.gov.co/). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: mmartinezg@udea.edu.co
Introduction
Dengue is an arthropod-transmitted disease that has great
importance worldwide. An estimated 50 million cases of dengue
occur annually, especially in tropical and subtropical areas. In
2011, there were more than one million cases of dengue in the
Americas alone, almost 20,000 with hemorrhagic complications,
and an overall mortality rate of 0.07% [1]. In the last 50 years, the
incidence of the disease has increased 30-fold, and it has even
expanded into new geographic zones. This increase is due in part
to global climate change. For example, through 2010, the El Nin˜o
phenomenon has been associated with an increase in the number
of cases of dengue reported in Central and South America,
including Colombia [2].
Dengue is caused by the dengue virus (DENV, official
acronym), which is a member of the Flaviviridae family, genus
Flavivirus. The disease is transmitted by mosquitoes of the genus
Aedes (Diptera: Culicidae, Subgenus Stegomyia), with Aedes aegypti
being the main vector in urban areas [3]. Four serotypes of DENV
(1–4) can cause the disease, which can develop with a wide range
of symptoms. Some patients develop a mild, self-limiting illness,
while others progress into a severe illness characterized mainly by
plasma extravasation that can be hemorrhagic or non-hemor-
rhagic [4]. Several classifications of the disease have been
proposed; however, the most recent classification proposed by
the World Health Organization is based on severity levels (severe
and non-severe dengue). In addition, the non-severe dengue group
includes both patients with warning signs of developing severe
dengue and those who do not show these signs [5].
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Currently, there is no licensed vaccine to prevent the
development of the disease, nor is there any specific therapy
against DENV infection. For this reason, the search for antiviral
drugs derived from natural products or already licensed drugs that
could have prophylactic and/or therapeutic use is a research
priority [6]. Although in recent years a large number of studies
have evaluated drugs with antiviral activity [7], only some drugs,
such as chloroquine [8], balapiravir [9] and celgosivir [10], have
been tested in clinical trials, and none of these have been licensed
for use in humans.
The antiviral potential of Lovastatin (LOV) on DENV infection
in cell culture has recently been reported [11]. This effect was
reportedly due in part to faulty viral assembly [12]. A randomized
controlled trial to evaluate the effects of LOV on adult patients
infected with DENV has been proposed [13]. LOV is a drug that
inhibits the enzyme 3-hydroxy-3-methylglutaryl coenzyme A
(HMG-CoA) reductase [14]; this inhibition results primarily in
decreased cholesterol synthesis but also affects other cellular
processes such as isoprenoid synthesis and glycosylation due to the
inhibition of dolichol synthesis. However, statins can also have
‘‘pleiotropic’’ effects on other cellular activities that are not directly
dependent on cholesterol inhibition [15].
In vitro evaluations of compounds with antiviral potential are
very useful; however, pre-clinical assays using animal models are
essential for identifying the most promising drugs that can be
evaluated and used in the medium-term in infected patients.
Several DENV-infected mouse models have been used to model
pathogenesis and the immune response and also for medication
development and vaccine studies [16]. Among these is the AG129
mouse model, which is deficient in receptors for interferon (IFN)
types I and II (IFN-a/b and IFN–c, respectively).
The AG129 mouse model was established in 1995 to evaluate
the antiviral response against lymphocytic choriomeningitis virus
and vaccinia virus [17]. Several years later, this model was used to
evaluate the immune response that developed after the inoculation
of vaccine candidates against DENV [18]. In the last decade,
AG129 mice have turned out to be a useful tool to study dengue in
diverse fields, facilitating research in viral pathogenesis and
immunity against infection [19]. In addition, these mice have
been helpful in the evaluation of vaccine candidates [20] and drugs
with potential antiviral activity [21,22,23,24,25].
Considering the previously reported in vitro antiviral activity of
LOV and the utility of the AG129 mouse model for studying the
antiviral potential of certain compounds, our objective was to
evaluate the effect of LOV on viremia and survival in AG129 mice
infected with DENV-2.
Materials and Methods
DENV Production
The New Guinea strain DENV-2 (ATCC VR-1255) was kindly
donated by Dr. Richard Kenney (Division of Vector-Borne
Infectious Diseases, Centers for Disease Control and Prevention,
Ft. Collins, CO). For its production, C6/36 cells from Aedes
albopictus (ATCC CRL-1660) were grown in 5% fetal bovine serum
(Hyclone) at 28uC. The virus was passaged 10 to 15 times in tissue
culture and then titered. To obtain viral titers greater than 16107
PFU/ml, the supernatants were collected and centrifuged for 1 hr
at 30,000 g. The pellet was then resuspended in RPMI medium
and stored at 270uC until use. For inoculations, the virus was
resuspended in 50 ml of phosphate buffered saline (PBS) to a viral
concentration of 56105 PFU/ml or 16106 PFU/ml.
Ethics Statement
All of our experiments that involved the use of animals were
approved by the Animal Experiment Committee of the University
of Wisconsin and were carried out by properly trained researchers.
All procedures were carried out in accordance with institutional
guidelines and the National Institutes of Health Guide for the Care
and Use of Laboratory Animals.
Inoculation of AG129 Mice
AG129 mice were obtained from B&K Universal. Adult mice
(six to eight weeks) were kept under ad libitum feeding conditions
with 12 hr cycles of light and darkness. A 50-ml viral suspension
containing either 56105 or 16106 PFU/ml was inoculated
intraperitoneally. Animals were monitored for 30 min after
inoculation to check for possible secondary effects on behavior.
LOV Treatment
Recently, it has been reported that the antiviral effect produced
by LOV in cell culture varies depending on the experimental
strategy used. In cultures treated with LOV before inoculation
(pre-treatment), the amount of viral protein decreased significant-
ly, whereas in cultures receiving LOV after inoculation (post-
treatment), the amount of both protein and viral genome increased
significantly [11]. These results led us to postulate that, depending
on the timing of LOV administration, the drug could produce
antiviral effects through different mechanisms. For this reason, in
the AG129 mouse model, we decided to evaluate two treatment
schemes: pre- and post-inoculation treatment. Moreover, taking
into account previous reports of antiviral activity in the AG129
mouse model [21,22], the antiviral efficacy of LOV was defined in
terms of a decrease in viremia or an increase in survival.
Groups of six AG129 mice (six to eight weeks old) were
subjected to seven different treatment schemes: Pre-treatment with
single or three doses and post-treatment with early, late and two
doses or five and six doses) (Figure 1). Moreover, in each assay we
used three different types of controls groups: The ‘‘PBS’’ group
consisted of mice that were not treated with LOV and were not
infected but administered with PBS alone, the ‘‘CONTROL’’
group consisted of mice that were treated with LOV but were not
infected and the ‘‘CONTROL-WITHOUT-LOV’’ group con-
sisted of mice that were not treated with LOV but were inoculated
with DENV-2. In both experimental strategies (pre and post-
treatment), the viremia levels, loss of body weight and the survival
rate of the CONTROL WITHOUT LOV group was compared
with the treated groups. Finally, the CONTROL group was used
to guaranty that the dose of LOV was not toxic.
In the treated groups, 200 mg/kg/day of LOV (Merck) was
prepared in 50 ml PBS and administered orally. This dose was
established by considering previous reports on the antiviral effect
of LOV in mice infected with respiratory syncytial virus [26]. In
that study, the authors tested three different doses of LOV: 0.5, 1
and 5 mg/day. Taking into account the average weight of a mouse
(approximately 25 g), those doses correspond to human doses of
20, 40 and 200 mg/kg/day, respectively. We chose to use the
200 mg/kg/day dose (equivalent to 5 mg/day). The animals were
monitored daily, and clinical signs (body weight, hackle hair,
diarrhea, lethargy and paralysis) and the survival rate were
evaluated until the completion of the study (eight days). Animals
that showed clinical signs of severe illness prior to ending the study
were sacrificed immediately by CO2 asphyxiation.
Anti-Dengue Activity of Lovastatin in AG129 Mice
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Viremia Quantification from Blood Samples
At three and five days post-inoculation, blood samples were
collected (approximately 100 ml) from immobilized animals by
saphenous vein puncture. Serum samples were obtained by
centrifugation after the blood coagulated. Viremia was quantified
by a plaque formation assay in VERO cells. For this assay, 56104
cells were seeded per well in a 24-well plate, and triplicate serial
dilutions of each sample (1021–1025) were prepared in DMEM
and added to the cells. The serum was removed 1 hr after
inoculation, and semisolid media was added (DMEM with 1.5%
carboxymethylcellulose and 2% FBS). After seven days of
incubation, the plates were stained with crystal violet and counted
to obtain the titer in PFU/ml.
Tissue Collection for Histopathological Analysis
Several animals were sacrificed at eight days post-inoculation by
CO2 asphyxiation. The skin of each animal was then cleaned with
70% antiseptic alcohol, and tissues (spleen and liver) were
dissected using surgical instruments. After dissection, the tissues
were fixed in 10% formaldehyde for 48 hrs, processed in paraffin
and stained with hematoxylin and eosin.
Clinical Follow-up
The mice were monitored twice a day, and clinical signs (body
weight, hackle hair, diarrhea, lethargy and paralysis) were
recorded. The duration of the study was eight days (endpoint),
but animals that showed clinical signs of severe illness prior to the
end of the study were sacrificed immediately by CO2 asphyxiation,
in accordance with the guidelines of the Animal Experimentation
Committee. The survival rate of each group was recorded daily
until the end of the study.
Statistical Analysis
The viral titers in PFU/ml were tested for normality of
distribution using a Kolmogorov–Smirnov test. When the titers
had a normal distribution, an ANOVA-LSD test was used to
compare levels of viremia between the treated and untreated
groups. When the viral titers in PFU/ml did not have a normal
distribution, we used a Kruskal-Wallis test to compare levels of
viremia between treated and untreated groups. Kaplan-Meier
survival curves were drawn and a Wilcoxon test was used to
compare the survival between treated and untreated groups.
Finally, to compare the average survival rates between treated and
Figure 1. Mice treatment schemes. Groups of six AG129 mice were subjected to seven treatment schemes. The effect of LOV on viremia and
survival rate before viral inoculation (pre-treatment) was evaluated in two experimental groups: single dose (only one dose 24 hours before viral
inoculation) and three doses (72, 48 and 24 hours before viral inoculation). The effect of LOV on viremia and survival rate after viral inoculation (post-
treatment) was evaluated in three experimental groups: Early dose (only one dose 24 after viral inoculation), late dose (only one dose 48 after viral
inoculation) and two doses (24 and 48 hours after viral inoculation). Finally, two other groups were used to evaluate the effect of multiple LOV doses,
administered only post-inoculation, on the survival rate (groups five and six doses). In the first five groups, at three days post-inoculation, blood
samples were collected and viremia was quantified by a plaque formation assay in VERO cells. The black triangles indicate the day of viral inoculation,
the red arrows indicate the days when the clinical signs were monitored, and the red lines indicate the experimental groups in which viremia or
survival was measured. In all groups, animals were monitored twice a day and clinical signs (body weight, hackle hair, diarrhea, lethargy and paralysis)
and survival rates were evaluated until day eight days, when the animals were sacrificed by CO2 asphyxiation.
doi:10.1371/journal.pone.0087412.g001
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untreated groups, the ANOVA-LSD test was used. In all cases, p-
values less than 0.05 were considered statistically significant.
Results
Comparison of Viremia Levels and Survival Rates of Mice
Infected with Different Doses of the Virus
To determine the optimal dose for infection and the time of the
highest levels of viremia, groups of six mice were infected
intraperitoneally with either 56105 or 16106 PFU/ml of the
New Guinea strain of DENV.
At three and five days post-inoculation (dpi), serum samples
were collected to quantify viremia by plaque assay in VERO cells.
At 3 dpi, 4.16104 PFU/ml were detected when a high dose of the
virus was inoculated, while half the dosage only produced a
quarter of the viremia (1.26104 PFU/ml). Independently of the
inoculated dose, there was a 70% decrease in viremia at 5 dpi
(9.76103 with a high dosage of the virus and 2.56103 with half the
dosage) (Figure 2A). Clinical signs and weight were recorded over
twelve days. In the two infected groups, a considerable loss of
weight was recorded compared to the control group inoculated
with PBS. Weight loss began at 4 dpi and was maintained until
days 8 (24.6%) and 12 (24.6%) in mice inoculated with the higher
(16106 PFU/ml) and lower (56105 PFU/ml) doses of virus,
respectively (Figure 2B). This weight loss was associated with the
development of paralysis that prevented the mice from moving
and getting food. In contrast, we found that the average survival
(9.461.6 days) was significantly greater in the group inoculated
with 56105 PFU/ml compared to mice inoculated with 16106
PFU/ml (4.861.6 days) (p,0.001) (Figure 2C–D). When animals
showed clinical signs of severe paralysis with or without weight loss
greater than 20%, they were sacrificed immediately by CO2
asphyxiation. The average survival rate was calculated based on
the sum of days that each mouse survived (until death or sacrifice)
over the number of mice in each experimental group. Because
mice inoculated with 16106 PFU/ml developed higher levels of
viremia, this dose was used for subsequent assays.
Effect of Pre-treatment with LOV on Viremia and Survival
Rate of DENV-2-infected Mice
Because recent reports have shown that the antiviral effect of
LOV in vitro is dependent on the treatment scheme used (before or
after inoculation), these same strategies were used in the in vivo
AG129 mouse infection model. To determine the effect of LOV
administered prior to viral inoculation (pre-treatment), groups of
six mice were treated with a single dose (24 hrs) or three doses (72,
48 and 24 hrs) before inoculation with DENV-2 (Figure 1).
Moreover, three different types of control groups were used (See
Materials and Methods section). In the group pre-treated with
three LOV doses, there was a significant 21.8% reduction in
viremia compared to the control group without LOV (p,0.001)
(Table 1). Viremia was not significantly reduced in mice treated
with a single LOV dose (reduction of 3.0%) (Figure 3A). In the
groups treated with one or three LOV doses, weight loss was
reduced compared to the control group without LOV (18.6% and
15.1%, respectively, compared to 24.0%) (Figure 3B). Based on
Kaplan-Meier analyses, we found a significant increase of survival
in the groups treated with one or three doses compared to the
control group without LOV (p,0.05). This result is consistent with
the average survival rates, which significantly increased (p,0.001)
in the groups treated with one or three doses compared to the
control group without LOV (7.3361.0 and 7.1760.9 days,
respectively, versus 4.861.6 days) (Figure 3C–D). The LOV
treatment alone did not affect the weight or survival time of
treated mice in the control group. However, despite the reductions
in viremia and weight loss and the increased survival rate observed
following LOV treatment, some animals in this experimental
group (pre-treatment) developed severe paralysis and were
sacrificed by CO2 asphyxiation the moment these signs started
to develop.
Effect of LOV Post-treatment on Viremia and Survival
Rates of DENV-2-infected Mice
We next evaluated the effect of LOV administered after viral
inoculation (post-treatment). Groups of six mice were treated in
three schemes: a single dose administered at 24 hours post-
inoculation (hpi), a single dose administered at 48 hpi or two doses
administered at 24 and 48 hpi. Moreover, three different types of
controls groups were used (see the Materials and Methods section).
The viral titer from mice treated at 24 hpi (4.36104 PFU/ml) was
not different from the titer of mice without LOV (4.26104 PFU/
ml). Surprisingly, in groups treated with a single dose at 48 hpi or
with two doses (24 and 48 hpi), we found higher serum viral titers
(5.26104 and 5.16104 PFU/ml, respectively) compared to the
control group without LOV (4.26104 PFU/ml) (24.6% and 21.7%
increases, respectively; p,0.001) (Figure 4A and Table 1). Weight
loss in infected animals was 24%, while LOV treatment at 24, 48
and 24+48 hpi reduced weight loss to only 8.0%, 13.0% and
5.3%, respectively (Figure 4B). Using Kaplan-Meier analyses, we
found a significant increase of survival in all three groups
compared to the control group without LOV (p,0.05). The
average survival rate of the untreated animals was 4.861.5 days.
LOV treatment in the three post-treatment schemes significantly
increased the survival rate to 7.360.5 days in the group
administered a single dose at 24 hpi and 6.861.3 days in the
group administered a single dose at 48 hpi. The survival rate in
the group administered two doses was 6.561.4 days (Figure 4C–
D). LOV treatment alone did not affect weight or survival time in
the treated mice, as is indicated by the results observed in the
CONTROL group. In these animal groups, some individuals
developed severe paralysis and had to be sacrificed.
Effect of Multiple LOV Doses Administered Post-
inoculation on the Survival Rate of DENV-2-infected Mice
To evaluate whether using multiple doses of LOV could
increase the survival rate, groups of six mice were inoculated with
DENV-2 (16106 PFU/ml) and treated with 200 mg/kg/day of
LOV every 24 hrs for five or six days. Based on Kaplan-Meier
analyses, we found a significant increase in survival in the groups
treated with both treatment schemes compared to the control
group without LOV (p,0.05). Specifically, the average survival
rate was increased to 6.761.5 days in the five-dose group and
7.161.4 days in the six-dose group compared with the untreated
control group (4.861.6) (Figure 5A–B).
Histopathological Analysis
Spleens and livers of mice from each of the evaluated groups
were dissected on day eight. Tissues were fixed and embedded in
paraffin before being stained with hematoxylin and eosin. Tissue
samples were examined at high resolution using an optical
microscope. Below, we describe the observations for each
experimental group.
Uninfected and untreated control mice. In the spleen,
there was a conserved architecture in the white and red pulp
(Figure 6A), and moderate levels of erythropoiesis were present
without megaloblastic changes (Figure 6D). The liver portal space
lacked congestion or inflammatory infiltration (Figure 7A). The
Anti-Dengue Activity of Lovastatin in AG129 Mice
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sinusoids did not present congestion (Figure 7D), and there was no
hyperplasia in the Kupffer cells (Figure 7G), nor was there
extramedullary erythropoiesis (Figure 7J).
Untreated infected mice. In the spleen, we observed red
pulp expansion with white pulp reduction (Figure 6B) and
extramedullary erythropoiesis with megaloblastic changes
Figure 2. Effect of viral dose on viremia and survival rate of AG129 mice. Groups of six mice were inoculated intraperitoneally with a high
viral dose of 16106 PFU/ml (dark bars) or a low viral dose of 16105 PFU/ml (grey bars) to determine the optimal dose of infection and time of
occurrence of the highest levels of viremia. A. Plaque assay of infected VERO cells to quantify serum viremia at 3 and 5 dpi. Bars represent the
standard error of the mean (SEM). B. Average body weight percentage, recorded every two days until the animals died or were sacrificed. C. Kaplan-
Meier curve showing the survival rates of both groups from day 0 to day 12. D. Comparison of the survival rates of the two groups. Mice inoculated
with 16106 PFU/ml developed higher levels of viremia at day 3.
doi:10.1371/journal.pone.0087412.g002
Table 1. Viral titer in different treatment schemes compared with the control without LOV group.
TREATMENT SCHEME NUMBER OF DOSES VIRAL TITER (PFU/ml) p VALUE
PRE WITHOUT LOV 4.79E+04 –
SINGLE DOSE 4.65E+04 0.447
THREE DOSES 3.75E+04 0.000
POST WITHOUT LOV 4.20E+04 –
EARLY DOSE 4.30E+04 0.383
LATE DOSE 5.20E+04 0.000
TWO DOSES 5.20E+04 0.001
In all comparisons, p-values less than 0.05 were considered statistically significant.
doi:10.1371/journal.pone.0087412.t001
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(Figure 6E). The liver showed congestion of the portal venule with
the presence of a lymphocytic infiltrate (Figure 7B), sinusoidal
congestion (Figure 7E), hyperplasia of Kupffer cells (Figure 7H)
and abundant extramedullary erythropoiesis foci (Figure 7K).
Infected mice treated with LOV. In the spleen, a slight
depletion of the white pulp (Figure 6C) and mild extramedullary
erythropoiesis without megaloblastic changes (Figure 6F) were
observed. The liver exhibited congestion of the portal venule with
little lymphocytic infiltrate (Figure 7C), little sinusoid congestion
(Figure 7F), hyperplasia of the Kupffer cells (Figure 7I) and scarce
extramedullary erythropoiesis foci (Figure 7L).
Discussion
Despite the large number of drugs that have been shown to have
antiviral activity against DENV in in vitro models, few have been
evaluated in animal models and only three drugs (chloroquine,
balapiravir and celgosivir [8,9,10] have been tested in clinical
assays in humans. One of the greatest difficulties in using antiviral
drugs in humans is the licensing of new molecules, a process that
can take many years. For this reason, in vitro and in vivo evaluation
of licensed drugs that have been used and tested previously and
have a low health risk (second-use drugs) is an interesting
alternative in the search for new antivirals. Taking into account
the advantages of evaluating second-use drugs, the present study
demonstrates the effect of LOV on DENV infection in the AG129
mouse model.
Figure 3. Effect of LOV treatment before viral inoculation (pre-treatment). Groups of six mice were treated with LOV (200 mg/kg/day) orally
prior to intraperitoneal inoculation with 16106 PFU/ml of virus. One group was treated with a single dose (24 hrs before viral inoculation), and the
other group was treated with three doses (72, 48 and 24 hrs before viral inoculation). Three types of controls groups were used. The ‘‘PBS’’ group
consisted of mice that were not treated with LOV and were not infected, the ‘‘CONTROL’’ group consisted of mice that were treated with LOV but
were not infected and the ‘‘CONTROL WITHOUT LOV’’ group consisted of mice that were not treated with LOV but were inoculated with DENV-2. The
viremia and survival rates were compared between the control without LOV group and the treated groups (single- and three-dose groups). A. Plaque
assay of infected VERO cells to quantify serum viremia at 3 dpi. Bars represent the standard error of the mean (SEM). B. Average body weight
percentage, recorded every two days until the animals died or were sacrificed. C. Kaplan-Meier curve showing the survival rates of the untreated
group and groups treated with one or three doses of LOV. D. Comparison of survival rates between the untreated group and groups treated with one
or three doses. Asterisks in A and D indicate statistically significant differences between the treated LOV groups and the control without LOV group.
In the group pre-treated with three LOV doses, there was a significant reduction in viremia. Moreover, the survival rates were increased in both
groups (pre-treated with one or three doses).
doi:10.1371/journal.pone.0087412.g003
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To determine the optimal dose of infection and time of
occurrence of the highest levels of viremia, preliminary experi-
ments were performed in our lab to evaluate viremia from day 1 to
day 9. We found that the viremia had a maximal peak at day 3,
and at day 7 was almost absent (data not shown) as had been
reported previously [18,21]. We found that with a high viral dose,
(16106 PFU/ml) viremia can reach titers on the order of 4.16104
PFU/ml, while titers reached with a low viral dose (56105 PFU/
ml) were four times lower (1.26104) (Figure 2A). This dose-
dependent effect has been reported previously in AG129 mice
inoculated with the DENV-2 strain TSV01 [21] or with the
DENV-2 strain D2Y98P [27]. With both viral doses (56105 or
16106 PFU/ml), the highest viremia level was measured at 3 dpi,
but the viral load in the blood was significantly lower (greater than
70% reduction) at 5 dpi. These studies agree with previous results,
in which inoculations with the DENV-2 strain TSV01 led to a
peak in viremia levels at 3 dpi, followed by an 85% reduction in
viremia at 5 dpi [21]. With the DENV-2 strain D2Y98P, the
viremia peaked at 3 dpi with a reduction .90% at 5 dpi [27].
This reduction could be related to the activation of an immune
response characterized by the appearance of IgM antibodies
(beginning at 3 dpi) and neutralizing IgG antibodies (beginning at
4 dpi) [21]. Because mice inoculated with a high viral dose (16106
PFU/ml) developed higher levels of viremia and the viremia had
its maximal peak at 3 dpi, that dose was used for subsequent assays
and the viremia was evaluated only at 3 dpi. When comparing the
survival of the two groups, we found that, in the group inoculated
with the higher dose of virus, more than 70% of the mice had died
by 5 dpi, and 100% of the mice were dead by 8 dpi (Figure 2C–
D). A previous study using the same strain (New Guinea) reported
Figure 4. Effect of LOV treatment after viral inoculation (post-treatment). Groups of six mice were treated with LOV (200 mg/kg/day) orally
with three treatment schemes: a single dose 24 hrs after inoculation (early dose), a single dose 48 hrs after inoculation (late dose) or two doses after
inoculation (24 and 48 hrs). Inoculations were administered intraperitoneally with a viral dose of 16106 PFU/ml. Three types of control groups were
used. The ‘‘PBS’’ group consisted of mice that were not treated with LOV and were not infected, the ‘‘CONTROL’’ group consisted of mice that were
treated with LOV but were not infected and the ‘‘CONTROL WITHOUT LOV’’ group consisted of mice that were not treated with LOV but were
inoculated with DENV-2. The viremia and survival rates were compared between the control without LOV group and the treated groups (early, late
and two doses groups). A. Plaque assay of infected VERO cells to quantify serum viremia at 3 dpi. Bars represent the standard error of the mean (SEM).
B. Average body weight percentage, recorded every two days until the animals died or were sacrificed. C. Kaplan-Meier curve showing the survival
rates of the untreated group and the three treated groups. D. Comparison of survival rates between the untreated group and the three treated
groups. Asterisks in A and D indicate statistically significant differences between the treated LOV groups and the control without LOV group. In the
groups treated with a single dose at 48 h after viral inoculation or with two doses (24 and 48 hpi), there was a significant increase in viremia.
Moreover, the survival rates were increased in the three groups.
doi:10.1371/journal.pone.0087412.g004
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75% mortality at 8 dpi and 100% mortality at 14 dpi [22]. In
addition, the infected animals lost increasing amounts of weight
before death (Figure 2B). A possible explanation for this weight
loss is the development of paralysis, which prevents the mice from
moving around to obtain food. The development of paralysis has
been described in AG129 mice infected with neuroadapted [18]
Figure 5. Effect of prolonged LOV treatment on the survival of infected mice. Groups of six mice were subjected to prolonged treatment
with LOV (200 mg/kg/day) orally after viral inoculation (post-treatment). The first group received a daily dose for five days (24, 48, 72, 96 and 120 hrs)
and the second group received a daily dose for six days (24, 48, 72, 96, 122 and 144 hrs). Inoculations were administered intraperitoneally with a viral
dose of 16106 PFU/ml. Three types of controls groups were used. The ‘‘PBS’’ group consisted of mice that were not treated with LOV and were not
infected, the ‘‘CONTROL’’ group consisted of mice that were treated with LOV but were not infected and the ‘‘CONTROL WITHOUT LOV’’ group
consisted of mice that were not treated with LOV but were inoculated with DENV-2. The survival rates were compared between the control without
LOV group and treated groups (five and six doses groups). A. Kaplan-Meier curve showing the survival rates of the untreated group and the two
treated groups. B. Comparison of the survival rates of untreated and treated groups. Asterisks indicate statistically significant differences between
treated LOV groups and the control without LOV group. Both treatment schemes, using multiple doses of LOV, significantly increased the survival
rates.
doi:10.1371/journal.pone.0087412.g005
Figure 6. Histopathological analysis of spleen sections from AG129 mice under different experimental conditions. A, D. Untreated
and uninfected control mice. B, E. Untreated infected mice. C, F. LOV-treated infected mice. A–C. Comparison between red and white pulp in spleen
sections. In normal mice there was a conserved architecture of both pulps (A). In untreated infected mice, expansion of the red pulp was observed
with depletion of the white pulp (B). In LOV-treated infected mice, a slight expansion of the red pulp was observed, but loss of the white pulp was not
as severe as in untreated animals (C). D–F. Erythropoiesis comparison. In untreated infected mice, massive erythropoiesis was observed with
megaloblastic changes (E). In normal mice (C) and treated mice (F), erythropoiesis was minor and no megaloblastic changes were observed.
doi:10.1371/journal.pone.0087412.g006
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and non-neuroadapted [28] strains of DENV inoculated intraper-
itoneally or intravenously and could be related to encephalitis
development. Although encephalitis has also been reported in
SCID mice inoculated intracerebrally with neuroadapted strains of
DENV [29], neuronal infection by DENV is a controversial issue.
Some authors have detected viral antigens and have isolated virus
from nervous tissue [18] of mice inoculated by methods other than
intracerebral inoculation, while others report a complete absence
of viral antigens in the brain [30]. The neurotropism of DENV
and the development of paralysis in DENV-infected mice are
important observations. However, they make it difficult to use this
strain for antiviral evaluations because when animals develop
paralysis and lose more than 20% of their body weight, according
to the regulations of the animal experimentation committee, they
must be sacrificed immediately to avoid suffering.
In humans, it has been proposed that viral load is directly
related to the severity of the disease and therefore, the survival of
infected patients. Patients who develop severe dengue (with
hemorrhage or hypovolemic shock) have higher titers than patients
with milder forms of the disease [31,32]. However, this
relationship is controversial because no differences in viremia
levels were found between adult patients with severe and non-
Figure 7. Histopathological analysis of liver sections from AG129 mice under different experimental conditions. A, D, G, J. Untreated
and uninfected control mice. B, E, H, K. Untreated infected mice. C, F, I, L. LOV-treated infected mice. A–C. Comparison between venular portal
sections. In infected mice (B) there was congestion with chronic inflammatory lymphocytes compared with normal mice (A), and in mice treated with
LOV, the infiltration was lower (C). D–F. Sinusoids comparison. Sinusoidal congestion was observed in untreated infected mice (E), and this was
reduced in LOV-treated mice (F). In normal mice, there was no congestion (D). G–I. In LOV-treated (I) or untreated (J) mice there was hyperplasia of
Kupffer cells compared with normal mice (G). J–L. In infected mice, massive extramedullar erythropoiesis was observed (K). In LOV-treated mice,
erythropoiesis was minor and the number of outbreaks was lower (L). In untreated and uninfected control mice, erythropoiesis was not observed (J).
doi:10.1371/journal.pone.0087412.g007
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severe forms of the disease in some studies [33]. Our results
indicate that the progression of the disease depends on the initial
viremia peak, being slower in mice with lower viremia at 3 dpi.
These results agree with those of other studies, which reported that
inoculation with a high viral dose led to animals dying a few days
after the peak of viremia, whereas infection with a low viral dose
led to asymptomatic dissemination with animals dying after the
virus had been cleared [34]. However, regardless of the initial
viremia levels, the mice end up developing paralysis, which is one
of the disadvantages of the AG129 model. As we mentioned
above, when animals develop paralysis they cannot move around
to obtain food, therefore they lose weight (in some cases more that
20%) and according to the regulations of the animal experimen-
tation committee, they must be sacrificed immediately to avoid
suffering. This made it difficult, for example, to make antiviral
evaluations in the long term.
Taking into account that the infection of AG129 mice with the
New Guinea strain DENV-2 results in paralysis, it would be
desirable to use a different strain that results in a viscerotropic
infection type, such as the D2S10 strain DENV-2. This strain
causes thrombocytopenia and vascular leakage in infected mice,
characteristics more commonly associated with the infection in
humans [35]. Recently, a mouse model has been developed that
does not require immunocompromised AG129 mice. In this
model, C57BL/6 mice are used, which are deficient in only the
IFN-a/b receptor. The mice are infected with a different DENV-2
strain (D220) derived from the D2S10 strain. This D220 strain
DENV-2 virus causes morbidity and mortality at a ten-fold lower
dose than its parental strain, D2S10 [36]. For this reason, it would
be a model more relevant for dengue studies (including antiviral
evaluations). However, until now, this model has not been used for
this type of study, and the AG129 model continues to be the most
important model for evaluating possible antiviral candidates
[16,37].
In this study, we found only a single significant decrease of
viremia (21.8%) (Figure 3A) among the groups that were treated
with three doses of LOV prior to viral inoculation. LOV treatment
is known to decrease the amount of cholesterol in the cell
membrane [14], where it is an important component of lipid rafts
[38]. These structures are important for DENV entry into its main
cell targets, including monocytes/macrophages [39]. Taking into
account the mechanisms of action described for statins, the
antiviral effect of LOV could be related to its blocking of DENV
cell entry, because the virus requires cholesterol-rich microdo-
mains during its replication cycle [39] or because cholesterol is
necessary for viral trafficking in late endosomes [40]. The antiviral
effect could also be due to damage to isoprenylated proteins, which
are required to complete the viral replication cycle once the virus
enters the cell [41,42]. Therefore, in mice treated with three
consecutive doses of LOV, the drug might decrease the levels of
cholesterol in the membrane, thus affecting the entry of the virus
into the cell and leading to a decrease in viremia. It is possible that
this effect might be related to the number of doses used, with one
dose not sufficient to decrease cholesterol in the membrane. This
scenario is consistent with the results of a previous study of rat
hepatocytes, in which cholesterol inhibition was dependent not
only on the LOV dose used but also on the duration of treatment
[43].
Surprisingly, when animals were treated with two doses of LOV
after viral inoculation (post-treatment experimental strategy), an
increase in viremia was observed. It is known that LOV not only
decreases cholesterol synthesis but also triggers pleiotropic effects
that are independent of cholesterol inhibition [44]. For example,
LOV inhibits the migration of inflammatory cells [45] by blocking
the expression of leukocyte function antigen 1 (LFA-1), which
binds to the cellular adhesion molecule ICAM-1 [46]. The
formation of this LFA-1-ICAM-1 complex is responsible for the
recruitment of leukocytes to sites of infection [47,48]. As
mentioned above, the correlation between viremia and disease
progression/severity is not completely clear [31,32,33]. However,
it has been demonstrated that the rapid removal of infected cells
facilitates viral dissemination and thus increases the severity of the
disease [49]. In contrast, mutant viruses that do not disseminate as
easily to other tissues cause a transitory viremia increase that
delays the progression of the disease [50]. It is likely that LOV
could delay the migration of infected cells (monocytes and
macrophages) to other tissues, thus inducing higher serum viral
titers and delaying the progression to severe illness. However,
when LOV treatment is removed, the infected cells can then
migrate normally, leading to disease development. This hypothesis
is in agreement with the histopathological analysis demonstrating
that, in the livers of infected mice treated with LOV, there was a
reduction in the infiltration of inflammatory cells, which were
present in untreated infected mice (Figure 6A–C).
Despite our finding of increased survival rates in both treatment
schemes (pre- or post-inoculation) as shown in the survival curves
(Figure 3C–D, 4C–D and 5A–B), neither treatment was effective
in preventing the death of the mice.
The post-treatment scheme is more similar to therapy in
humans, because therapy would only be administered after
infection. Thus, the results obtained here must be applied carefully
because the post-inoculation treatment scheme increases viremia,
and we do not know how this increase might affect disease
progression in humans. As mentioned above, the relationship
between viremia and disease severity is controversial. Therefore,
additional studies are required to elucidate the mechanisms
involved in the delay of dengue progression induced by LOV in
spite of an increase in viremia.
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